This important study identifies PRRT2 as an auxiliary regulator of Nav channel slow inactivation, proposing that PRRT2 facilitates entry into, and delays recovery from, the slow-inactivated state. The ...

Note: On January 30, 2025 the FDA approved the first-in-class non-opioid analgesic Journavx (suzetrigine) for the treatment of moderate to severe acute pain in adults. The novel drug reduces pain by ...

Channel Therapeutics Corporation, a clinical-stage biotechnology company focused on non-opioid pain treatments, expressed encouragement regarding Vertex Pharmaceuticals' recent Phase 2 data for ...

Introduction: Cardiomyocyte alignment increases over time during normal heart development. This alignment is associated with aligned mechanical tension and plays a key role in electromechanical ...

A new study adds to evidence which suggests treating breast cancer patients with sodium channel blockers could be a promising future treatment to prevent the spread of cancer during the gap between ...

Abstract: This paper explains how faults or anomalies might be indicated by changes in the initial condition of tissues, particularly the flow of potassium and sodium ions with leaks. Convolutional ...

Lipid-derived electrophiles (LDEs) are a class of highly reactive molecules formed from the breakdown of lipid hydroperoxides. Despite evidence showing that elevated production of LDEs during ...

SCN2A related-disorders, although rare in the general population, are one of the more common single-gene neurodevelopmental conditions characterized by infantile seizures, autism spectrum disorder and ...

Hyperactive channels were generally associated with seizure onset in the first week of life. More impaired channel function was more common when the age of seizure onset was older. In fact, almost all ...